From the 2022 Joint Annual
Meeting (recorded 6/29/2022)
Presented by Rashmi Kanagal-Shamanna, MD
The application of NGS for molecular profiling for AML and MDS has allowed for improved classification, prognostication, and targeted therapeutics. We are now witnessing the emergence of advanced techniques that can complement conventional cytogenetic analysis to allow for improved precision medicine care. This presentation will highlight some of these techniques, and their applications in the care of patients with myeloid malignancies.
At the conclusion of this presentation, participants will be able to:
- Summarize the standard technologies currently used in clinical laboratories for work-up of hematological malignancies
- Identify potential new techniques that can complement conventional cytogenetic studies in clinical laboratories
- Identify the importance of genomic data for diagnosis, prognostication and therapeutics
ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of CMB (Cytogenetics) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.
This Advanced-level program is appropriate for laboratory professionals working in clinical, public health and academic settings